GeneDX shares plunge 45% after revenue miss, law firm probes potential securities violations

GeneDX Holdings Corp. shares dropped over 45% following a first-quarter revenue report below analyst expectations and a lowered full-year revenue forecast for 2026. The company had previously reaffirmed its outlook in February, but the updated guidance now projects revenue between $475 million and $490 million, down from $540-$555 million. Law firm Block & Leviton is investigating possible securities law violations and is encouraging affected investors to contact them for potential recovery of losses. Investors who purchased GeneDX stock and suffered losses may be eligible to join the investigation or legal action.